Maximize animal well-being and research quality with our enrichment solutions.
Get our free guide to translational models that deliver reliable data and de-risk decisions early.
New research model pricing is now available!
Secure your source for quality antibody production. Learn how our experience and flexibility can meet your needs for both small scale and large scale production.
Learn how our whole slide imaging and precision AI-driven quantitative image analysis can support your drug discovery and development projects.
Developing Antibody Drug Conjugate (ADC) therapeutics? Inotiv has mass spectrometry assays to quantify your ADC target protein in any sample type, including FFPE tissue, without antibodies. We have developed assays to 27 ADC targets for oncology and other therapeutic applications.
Inotiv delivers a broad array of nonclinical and analytical services from discovery through clinical development.
Inotiv provides the broadest range of research models and related services to pharmaceutical and biotech companies, government, academia, and other life science organizations.
June 8-11, 2026 Budapest, Hungary Booth #70 The 2026 Annual Congress of the European Association for Cancer Research (EACR 2026) is a four day congress dedicated to basic, pre...
June 21-24, 2026 San Diego, CA Booth # 7 We are living in an era of enormous scientific advancements that are paving the way for the discovery, development, and approval of novel d...
September 6-10, 2026 Edinburgh, Scotland Booth #TBD The 14th ICEM will offer 30 symposia, as well as 10 plenary lectures and a series of interactive poster sessions from scientists...
February 13, 2026 WEST LAFAYETTE, Ind., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a le...
February 09, 2026 First quarter fiscal 2026 revenue increased 0.8% compared to prior year quarter to $120.9 million First quarter fiscal 2026 operating loss increased 5.3% compared to prior year quarter to $16....
February 4, 2026 WEST LAFAYETTE, Ind., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a lea...
Undertaking a large-scale rederivation project can be complex and resource-intensive, with hundreds of animal lines at stake. Choosing the right commercial partner is the most critical step to ensure both scientific integrity and operational success.
Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.
Copyright © 2026 Inotiv. All Rights Reserved.